MPM Capital

MPM Capital, founded in 1997, is a leading venture capital firm based in Boston and San Francisco, specializing in biotechnology and life sciences investments. The firm has a robust portfolio, having invested in over 150 companies, including notable names like 23andMe, ReNAgade Therapeutics, and Argenx. MPM Capital's focus is on transforming innovative scientific discoveries into breakthrough medicines, particularly in oncology and other high-need therapeutic areas​. MPM Capital recently raised $850 million for its second Oncology Impact Fund, marking it as one of the largest biotech impact investment funds globally. This fund emphasizes investments in companies developing novel cancer therapies, reflecting MPM's deep commitment to addressing significant medical challenges. The firm's team includes seasoned professionals with extensive experience in research, drug development, and corporate strategy. Key team members like Dr. Luke Evnin and Dr. Ansbert Gadicke bring invaluable expertise to the firm, guiding its strategic investments and supporting portfolio companies through various growth stages​ .